Yescarta (axicabtagene ciloleucel)

pCPA File Number: 22285

Negotiation Status:

Active Negotiation

Indication(s):

for the treatment of adult patients with diffuse large B-cell lymphoma (DLBCL) or high-grade B-cell lymphoma (HGBL) that is refractory to first-line chemoimmunotherapy or that relapses within 12 months of first-line chemoimmunotherapy

Sponsor/Manufacturer:

Gilead Sciences Canada Inc.

CADTH Project Number:

PG0293

pCPA Engagement Letter Issued:

2023-09-26

Negotiation Process Concluded:

Not Applicable